Icon
+91 94997 68112
Login Register

FOUNDAYO - (EQ 0.8MG BASE, EQ 2.5MG BASE, EQ 5.5MG BASE, EQ 9MG BASE, EQ 14.5MG BASE, EQ 17.2MG BASE; TABLET)

ORFORGLIPRON CALCIUM None
EQ 0.8MG BASE, EQ 2.5MG BASE, EQ 5.5MG BASE, EQ 9MG BASE, EQ 14.5MG BASE, EQ 17.2MG BASE; TABLET
Less Than $1000 mn
None None
None None
None None
FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
Yes
FOUNDAYO Patent 1
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.